A wide range of substances and therapeutic methods has been developed to enhance immunotherapy effects in cancer patients [394, 396–399, 401–404], although combined application of sphingolipid-targeting agents and TNF-α pathway activating methods seems neglected. This evidence concerns the gene TNF and cancer.